C. Andrews

发表

Sequential administration of Prevnar 13™ and PNEUMOVAX™ 23 in healthy participants 50 years of age and older

Meihua Wang, M. Kohn, Temitope A Folaranmi, 2021, Human vaccines & immunotherapeutics.

Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults ≥50 years of age.

D. Greenberg, R. Rupp, J. Stek, 2018, Vaccine.

Six-Month Safety Data of Recombinant Vesicular Stomatitis Virus–Zaire Ebola Virus Envelope Glycoprotein Vaccine in a Phase 3 Double-Blind, Placebo-Controlled Randomized Study in Healthy Adults

R. Das, S. Halperin, R. Rupp, 2017, The Journal of infectious diseases.

Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older

H. Ikematsu, Shinn-Jang Hwang, M. Levin, 2018, The Journal of infectious diseases.

A phase I randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of a live-attenuated quadrivalent dengue vaccine in flavivirus-naïve and flavivirus-experienced healthy adults

K. Russell, R. Rupp, B. Coller, 2022, Human vaccines & immunotherapeutics.

Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase 1/2, randomised, double-blind, active comparator-controlled, multicentre, US-based trial.

N. Gallagher, R. Mularski, Julie M. Skinner, 2022, The Lancet. Infectious diseases.

The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70

A. Schaefer, Shinn-Jang Hwang, G. Icardi, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Quality of Life Impact of an Adjuvanted Recombinant Zoster Vaccine in Adults Aged 50 Years and Older

L. Cámpora, M. Levin, Robert W. Johnson, 2018, The journals of gerontology. Series A, Biological sciences and medical sciences.

Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial

E. Kerwin, J. Tica, F. Struyf, 2022, The Journal of infectious diseases.

Long-term Protection Against Herpes Zoster by the Adjuvanted Recombinant Zoster Vaccine: Interim Efficacy, Immunogenicity, and Safety Results up to 10 Years After Initial Vaccination

Hyo Youl Kim, Kenjiro Nakamura, A. Schaefer, 2022, Open forum infectious diseases.

P09 A Phase 2, randomized, double-blind study to evaluate the safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine (V116) in adults ≥50 years

R. Mularski, Neil J. Fraser, A. Sapre, 2023, JAC-Antimicrobial Resistance.

Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged ≥50 years: A randomized phase III trial (PNEU-PATH).

M. Oh, R. Dagan, J. Song, 2021, Vaccine.

119. A Respiratory Syncytial Virus Prefusion F Protein (RSVPreF3) Candidate Vaccine Administered in Older Adults in a Phase I/II Randomized Clinical Trial Is Well Tolerated

E. Kerwin, J. Tica, N. Dezutter, 2020, Open Forum Infectious Diseases.

Quality of Life Impact of an Adjuvanted Recombinant Zoster Vaccine in Adults Aged 50 Years and Older

L. Cámpora, M. Levin, Robert W. Johnson, 2018, The journals of gerontology. Series A, Biological sciences and medical sciences.

119. Safety and Reactogenicity of an Investigational Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine for Adults ≥ 60 Years of Age (RSVPreF3 OA): an Interim Analysis at 6 Months after Vaccination

Shinn-Jang Hwang, M. Lievens, C. Liu, 2022, Open Forum Infectious Diseases.

96. A Candidate Respiratory Syncytial Virus (RSV) Prefusion F Protein Investigational Vaccine (RSVPreF3 OA) Is Immunogenic when Administered in Adults ≥ 60 Years of Age: Results at 6 Months after Vaccination

Shinn-Jang Hwang, M. Lievens, C. Liu, 2022, Open Forum Infectious Diseases.